Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
58.37
-1.35 (-2.26%)
Mar 9, 2026, 3:00 PM CST
SHA:688399 Revenue
In the year 2025, Jiangsu Bioperfectus Technologies had annual revenue of 340.38M CNY, down -2.64%. Jiangsu Bioperfectus Technologies had revenue of 82.87M in the quarter ending December 31, 2025, with 1.66% growth.
Revenue
340.38M
Revenue Growth
-2.64%
P/S Ratio
14.72
Revenue / Employee
574.97K
Employees
586
Market Cap
5.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 340.38M | -9.23M | -2.64% |
| Dec 31, 2024 | 349.61M | -53.57M | -13.29% |
| Dec 31, 2023 | 403.18M | -5.13B | -92.72% |
| Dec 31, 2022 | 5.53B | 2.70B | 94.95% |
| Dec 31, 2021 | 2.84B | 1.10B | 63.19% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assure Tech (Hangzhou) | 453.58M |
| Beijing Bohui Innovation Biotechnology Group | 834.38M |
| Shanghai Obio Technology (Group) Corp. | 267.66M |
| ChemPartner PharmaTech | 1.07B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Pulike Biological Engineering | 1.10B |
| Hefei Lifeon Pharmaceutical | 1.47B |
| Innovita Biological Technology | 422.03M |